New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
04:55 EDTCMRX, CMRX, CMRX, CMRX, CMRX, CMRX, PFE, PFE, PFE, PFE, PFE, PFE, GILD, GILD, GILD, GILD, GILD, GILD, GSK, GSK, GSK, GSK, GSK, GSK, BMY, BMY, BMY, BMY, BMY, BMY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, AZN, AZN, AZN, AZN, AZN, AZN, SRPT, SRPT, SRPT, SRPT, SRPT, SRPTInternational Society for Antiviral Research to hold a conference
27th International Conference on Antiviral Research to be held in Raleigh, North Carolina on May 12-17.
News For CMRX;PFE;GILD;GSK;BMY;RHHBY;AZN;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 19, 2015
16:01 EDTGILDOptions Update; March 19, 2015
Subscribe for More Information
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
09:08 EDTGILDNew Gilead HIV drug likely to be approved in mid-2015, says Argus
Subscribe for More Information
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREOŽ ELLIPTAŽ), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
07:02 EDTRHHBYSigma-Aldrich signs exclusive distribution agreement with Roche
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
07:46 EDTRHHBYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
March 17, 2015
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
08:13 EDTRHHBYCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
07:07 EDTGSKVeeva says selected by GlaxoSmithKline for multichannel CRM
Subscribe for More Information
07:06 EDTGSKVeeva selected by GSK as global multichannel CRM partner
Subscribe for More Information
06:31 EDTGILDStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
16:00 EDTGILDOptions Update; March 16, 2015
Subscribe for More Information
07:32 EDTGSKEmergent BioSolutions signs agreements with GSK, Oxford University, NIAID
Subscribe for More Information
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information
06:40 EDTPFEPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use